Back to search
FDAFDA · Food and drugs·Recall number D-096-2013

Nalbuphine HCl Injection, 20 mg/mL, 10 mL Multiple-dose Fliptop Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-1467-01

Published December 26, 2012 · Recall initiated: November 21, 2012

Summary

FDA records drug Class II recall D-096-2013, published December 26, 2012 and initiated November 21, 2012. Recalling firm: Hospira, Inc.; Status: Terminated; Reported quantity: 145,400 vials; Lot: Lot #: 11-293-DK, Exp 05/01/13. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: Complains of a loose crimp applied to the fliptop vial; and a missing stopper and flip cap were received and therefore sterility cannot be assured.

What to do

Voluntary: Firm initiated · Letter

Get an email if NALBUPHINE HYDROCHLORIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
NALBUPHINE HYDROCHLORIDE
Manufacturer
Hospira, Inc.
Distributor
Nationwide and Puerto Rico.
Lot
Lot #: 11-293-DK, Exp 05/01/13
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Nalbuphine HCl Injection, 20 mg/mL, 10 mL Multiple-dose Fliptop Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-1467-01 recalled?

Yes. FDA published recall D-096-2013 on December 26, 2012. Reported hazard: Lack of Assurance of Sterility: Complains of a loose crimp applied to the fliptop vial; and a missing stopper and flip cap were received and therefore sterility cannot be assured.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: NALBUPHINE HYDROCHLORIDE.